A Review of Next-Generation Therapeutics and Contemporary Management of Myelofibrosis

A Review of Next-Generation Therapeutics and Contemporary Management of Myelofibrosis

Friday, December 9, 2022 in New Orleans, LA
Live Meeting -- Sheraton New Orleans, 3:00 PM CT
Rhythms Ballroom

Agenda

  • Overview of MF
  • Managing Newly Diagnosed Myelofibrosis
    • Managing treatment-naive MF and MF with no ruxolitinib failure
    • Challenging cases in intermediate-risk and high-risk MF
    • Recognizing patterns of first-line treatment failure in patients with MF
  • Second-line Treatment Options After First-line Failure
    • Including a discussion of emerging agents and relevant clinical trials
  • Managing Disease-Related and Treatment-Related Symptoms for Improved Patient Outcomes
  • Clinical Trial Spotlight of Key Abstracts at ASH 2022
  • Audience Question and Answer Session

Faculty

Program Director
Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Faculty
Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Faculty
Abdulraheem Yacoub, MD

Clinical Director of Ambulatory Hematology Clinics
Division of Hematologic Malignancies and Cellular Therapeutics
Department of Internal Medicine
The University of Kansas Cancer Center
Kansas City, Kansas

Goal Statement
The goal of this activity is to improve knowledge, confidence, and competence of healthcare professionals treating patients with myelofibrosis by leveraging recent and emerging data that must be considered in treatment decisions.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with myelofibrosis, including hematologists/oncologists, advanced care practitioners, pharmacists, and nurses.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Develop individualized treatment plans for patients with MF based on risk stratification and burden of symptoms
  • Plan evidence-based therapeutic strategies for patients with MF who are relapsed, refractory, or intolerant to prior JAK inhibitor therapy
  • Institute best practices for transitioning to a clinically appropriate second line therapy after first line treatment failure
  • Integrate supportive care plans into practice designed to monitor and manage treatment-related toxicities from new or novel MF treatments
  • Identify patients with MF who are eligible for enrollment on a clinical trial

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.